Key Takeaways JNJ won FDA approval to expand Akeega for BRCA2-mutated metastatic castration-sensitive prostate cancer.The phase III AMPLITUDE study showed the Akeega-prednisone combo cut progression or death risk by 54%.The label expansion moves Akeega into earlier treatment, building on its 2023 approval in resistant disease.Johnson & Johnson (JNJ) announced that the FDA approved its precision therapy, Akeega (niraparib and abiraterone acetate dual-action tablet), for a second indication in prostate cancer ...